{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:15:29Z","timestamp":1790306129534,"version":"4.1.0"},"reference-count":45,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"funder":[{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","award":["213520"],"award-info":[{"award-number":["213520"]}],"id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,9,10]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with severe eosinophilic asthma, characterised by a high disease burden, benefit from mepolizumab, which improves symptoms and reduces exacerbations, potentially leading to clinical remission in a subgroup. This study aimed to identify treatment response trajectories to mepolizumab for severe eosinophilic asthma and to assess the achievement of clinical remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from the Australian Mepolizumab Registry were used to assess treatment responses at 3, 6 and 12\u2005months. The treatment response trajectories were identified using a group-based trajectory model. The proportions achieving clinical remission at 12\u2005months, which was defined as well-controlled symptoms, no exacerbations and no oral corticosteroid (OCS) use for asthma management, were compared between trajectories, and baseline predictors of the trajectories were identified using logistic regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified three trajectory groups: Group 1, \u201cResponsive asthma with less OCS use\u201d (n=170); Group 2, \u201cResponsive late-onset asthma\u201d (n=58); and Group 3, \u201cObstructed and less responsive asthma\u201d (n=70). Groups 1 and 2 demonstrated higher proportions achieving clinical remission at 36.5% and 25.9%, respectively, compared to Group 3 with 5.7% (p&lt;0.001). Baseline predictors for assigned groups included lower OCS dose in Group 1; greater forced expiratory volume in 1\u2005s percentage predicted, higher Asthma Quality of Life Questionnaire score, higher OCS dose and nasal polyps in Group 2; with Group 3 as the reference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Treatment response to mepolizumab in severe eosinophilic asthma follows three trajectories with varying proportions achieving clinical remission and differing baseline characteristics. Treatment response variability may influence the achievement of clinical remission with mepolizumab therapy.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.00782-2024","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:25:14Z","timestamp":1728919514000},"page":"2400782","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma"],"prefix":"10.1183","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-652X","authenticated-orcid":false,"given":"Yuto","family":"Hamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-6821","authenticated-orcid":false,"given":"Dennis","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin S.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-1774","authenticated-orcid":false,"given":"Michael","family":"Fricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5212-2937","authenticated-orcid":false,"given":"Hayley","family":"Lewthwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Kritikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-3433","authenticated-orcid":false,"given":"John W.","family":"Upham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5865-489X","authenticated-orcid":false,"given":"Peter G.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"2025013008000826000_65.1.2400782.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00634-2017"},{"key":"2025013008000826000_65.1.2400782.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1608969"},{"key":"2025013008000826000_65.1.2400782.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2025013008000826000_65.1.2400782.4","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.jaip.2019.05.053","article-title":"Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma","volume":"7","author":"Comberiati","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025013008000826000_65.1.2400782.5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12890-016-0263-8","article-title":"Burden of asthma with elevated blood eosinophil levels","volume":"16","author":"Casciano","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2025013008000826000_65.1.2400782.6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13223-018-0241-1","article-title":"Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data","volume":"14","author":"Husereau","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2025013008000826000_65.1.2400782.7","first-page":"85","article-title":"Clinical and economic burden of elevated blood eosinophils in patients with and without uncontrolled asthma","volume":"23","author":"Casciano","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2025013008000826000_65.1.2400782.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2032506"},{"key":"2025013008000826000_65.1.2400782.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2025013008000826000_65.1.2400782.10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"2025013008000826000_65.1.2400782.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2025013008000826000_65.1.2400782.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02345-2019"},{"key":"2025013008000826000_65.1.2400782.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02420-2019"},{"key":"2025013008000826000_65.1.2400782.14","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jaip.2021.01.028","article-title":"Mepolizumab and oral corticosteroid stewardship: data from the Australian Mepolizumab Registry","volume":"9","author":"Thomas","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025013008000826000_65.1.2400782.15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"2025013008000826000_65.1.2400782.16","doi-asserted-by":"crossref","first-page":"1150162","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"2025013008000826000_65.1.2400782.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.01.037"},{"key":"2025013008000826000_65.1.2400782.18","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5R: results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025013008000826000_65.1.2400782.19","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/jpm13061020","article-title":"Clinical asthma remission obtained with biologics in real life: patients\u2019 prevalence and characteristics","volume":"13","author":"Sposato","year":"2023","journal-title":"J Pers Med"},{"key":"2025013008000826000_65.1.2400782.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00819-2023"},{"key":"2025013008000826000_65.1.2400782.21","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jaip.2019.02.011","article-title":"Novel trajectories for identifying asthma phenotypes: a longitudinal study in Korean asthma cohort, COREA","volume":"7","author":"Park","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025013008000826000_65.1.2400782.22","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.jaip.2019.12.002","article-title":"Trajectory analyses of adherence patterns in a real-life moderate to severe asthma population","volume":"8","author":"van Boven","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025013008000826000_65.1.2400782.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02583-2021"},{"key":"2025013008000826000_65.1.2400782.24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.chest.2024.02.048","article-title":"Azithromycin induced asthma remission in adults with persistent uncontrolled asthma: a secondary analysis of a randomised, double-blind, placebo-controlled trial","volume":"166","author":"Thomas","year":"2024","journal-title":"Chest"},{"key":"2025013008000826000_65.1.2400782.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"},{"key":"2025013008000826000_65.1.2400782.26","doi-asserted-by":"crossref","first-page":"bbab489","DOI":"10.1093\/bib\/bbab489","article-title":"Evaluating the state of the art in missing data imputation for clinical data","volume":"23","author":"Luo","year":"2022","journal-title":"Brief Bioinform"},{"key":"2025013008000826000_65.1.2400782.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.10.046"},{"key":"2025013008000826000_65.1.2400782.28","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to biologics and clinical remission in the adult German Asthma Net severe asthma registry cohort","volume":"11","author":"Milger","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025013008000826000_65.1.2400782.29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-024-02812-3","article-title":"Barriers to clinical remission in severe asthma","volume":"25","author":"Farinha","year":"2024","journal-title":"Respir Res"},{"key":"2025013008000826000_65.1.2400782.30","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13601"},{"key":"2025013008000826000_65.1.2400782.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1754OC"},{"key":"2025013008000826000_65.1.2400782.32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaip.2022.11.025","article-title":"Association between blood eosinophils and neutrophils with clinical features in adult-onset asthma","volume":"11","author":"Flinkman","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025013008000826000_65.1.2400782.33","doi-asserted-by":"publisher","DOI":"10.1111\/resp.14147"},{"key":"2025013008000826000_65.1.2400782.34","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025013008000826000_65.1.2400782.35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.arbres.2023.11.011","article-title":"Comparison of long-term response and remission to omalizumab and anti-IL-5\/IL-5R using different criteria in a real-life cohort of severe asthma patients","volume":"60","author":"Valverde-Monge","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"2025013008000826000_65.1.2400782.36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.23822\/EurAnnACI.1764-1489.318","article-title":"Variables predicting clinical remission among adults with severe asthma treated with biologic agents","volume":"56","author":"Ye\u015filkaya","year":"2024","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"2025013008000826000_65.1.2400782.37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/cea.12695","article-title":"Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma","volume":"46","author":"Sehmi","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"2025013008000826000_65.1.2400782.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"2025013008000826000_65.1.2400782.39","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaci.2024.03.023","article-title":"Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma","volume":"154","author":"Tang","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2025013008000826000_65.1.2400782.40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00117-2020"},{"key":"2025013008000826000_65.1.2400782.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.006"},{"key":"2025013008000826000_65.1.2400782.42","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025013008000826000_65.1.2400782.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.08.609"},{"key":"2025013008000826000_65.1.2400782.44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01499-2021"},{"key":"2025013008000826000_65.1.2400782.45","doi-asserted-by":"crossref","first-page":"00444-2022","DOI":"10.1183\/23120541.00444-2022","article-title":"Definitions of non-response and response to biological therapy for severe asthma: a systematic review","volume":"9","author":"Khaleva","year":"2023","journal-title":"ERJ Open Res"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00782-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:48:36Z","timestamp":1740376116000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00782-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,30]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1183\/13993003.00782-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00782-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}